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Abstract
Background
Patients who develop herpes zoster or herpes zoster ophthalmicus may be at risk for cere-
brovascular and cardiac complications. We systematically reviewed the published literature
to determine the association between herpes zoster and its subtypes with the occurrence of
cerebrovascular and cardiac events.
Methods/Results
Systematic searches of PubMed (MEDLINE), SCOPUS (Embase) and Google Scholar
were performed in December 2016. Eligible studies were cohort, case-control, and self-
controlled case-series examining the association between herpes zoster or subtypes of
herpes zoster with the occurrence of cerebrovascular and cardiac events including stroke,
transient ischemic attack, coronary heart disease, and myocardial infarction. Data on the
occurrence of the examined events were abstracted. Odds ratios and their accompanying
confidence intervals were estimated using random and fixed effects models with statistical
heterogeneity estimated with the I2 statistic. Twelve studies examining 7.9 million patients
up to 28 years after the onset of herpes zoster met our pre-defined eligibility criteria. Ran-
dom and fixed effects meta-analyses showed that herpes zoster, type unspecified, and
herpes zoster ophthalmicus were associated with a significantly increased risk of cerebro-
vascular events, without any evidence of statistical heterogeneity. Our meta-analysis also
found a significantly increased risk of cardiac events associated with herpes zoster, type
unspecified.
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Conclusions
Our results are consistent with the accumulating body of evidence that herpes zoster and
herpes zoster ophthalmicus are significantly associated with cerebrovascular and cardio-
vascular events.
Introduction
Approximately 95% of American adults have a latent varicella zoster virus (VZV) infection
arising from a primary infection, varicella (chickenpox) [1]. About one in every five individu-
als with latent VZV will develop herpes zoster (shingles), a reactivation of the virus that typi-
cally presents as a painful vesicular rash within a dermatome [2]. While this rash resolves in
several weeks, herpes zoster may produce additional complications including post herpetic
neuralgia, ocular pathologies, myelitis, and encephalitis [2]. Approximately 10–20% of patients
with shingles will have herpes zoster ophthalmicus, VZV reactivation in the ophthalmic divi-
sion of the trigeminal nerve, which lies close to the cerebral arteries [3].
Multiple case studies have reported the occurrence of stroke after the development of shin-
gles, but have not quantified the magnitude of risk associated with this viral reactivation [4–6].
Better understanding of this relationship is important to public health initiatives, since shingles
is both common and preventable through vaccination [7, 8]. Since prior meta-analyses neither
included more contemporary studies and have focused on cerebrovascular events to the exclu-
sion of cardiac events, a more current synthesis of the existing literature is warranted [9–12].
In this review, we systematically describe and evaluate the literature examining the association
between herpes zoster and the development of a variety of cerebrovascular and cardiac events
and provide an overview of previous meta-analysis.
Methods
Data sources and searches
This review was performed in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) [13] (S1 Checklist). The protocol for this study was
registered on the PROSPERO registry for systematic reviews (CRD42016045194) [14].
Searches on the PubMed1 (includes MEDLINE1 content) and Scopus1 (includes Embase1
content) electronic databases were performed in December 2016 to identify relevant articles.
Text headings and medical subject heading (MeSH) terms used in the searches included herpes
zoster, shingles, herpes zoster ophthalmicus, herpes zoster oticus, zoster sine herpete, herpes
zoster oticus, stroke, transient ischemic attack, myocardial infarction, angina, cardiac death,
coronary heart disease, coronary revascularization, and vascular diseases. This search strategy
emphasized terms for the most prevalent cerebrovascular and cardiovascular events [15] (S1
File). We reviewed the reference lists of eligible articles and performed searches on Google
Scholar and OAIster (database of the Open Archives Initiative) to identify additional research
not indexed by the searched databases.
Study selection
This review included studies that: (1) investigated the association between herpes zoster, or a
subtype of herpes zoster, with cerebrovascular and cardiovascular events as defined in the pri-
mary studies and included stroke, transient ischemic attack, myocardial infarction, angina,
Herpes zoster and cardiovascular events
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coronary heart disease, cardiac death, coronary revascularization, and vascular diseases; (2)
used a trial, cohort, case-control, case-crossover, or cross-sectional (with a temporal relation-
ship established between exposure and outcome) design; (3) were written in English; (4) were
published in a peer-review journal or as a conference paper; and (5) were published between
January 1, 1960 and December 28, 2016. Excluded studies did not meet the inclusion criteria
or (1) were a case-study/series, abstract (with no accompanying full text), review article, or
cross-sectional study without the temporal relationship established between the exposure and
outcome; or (2) examined primary VZV infection (i.e., chickenpox) as the exposure; or (3)
restricted to patients less than 18 years of age; or (4) studied immunocompromised popula-
tions (e.g., HIV, cancer).
Data extraction
One author (N.E.) reviewed all publication titles to eliminate articles that covered a subject not
relevant to this review, described a primary exposure that was not herpes zoster or its subtypes,
or used an immunocompromised, pediatric, or non-human sample. Two authors (N.E. and H.
T.) reviewed abstracts of the remaining articles to determine inclusion for assessment of the
full text. Discrepancies were resolved by group consensus and independent adjudication (R.
G.) if consensus could not be reached. One author (N.E.) extracted data onto a standardized
data collection form. Extracted information included study title and authors, year of publica-
tion, source of participants and sample size, mean age and gender composition of the study
sample, type of herpes zoster studied (e.g., herpes zoster, herpes zoster ophthalmicus), cerebro-
vascular and cardiovascular event outcomes (e.g., stroke, transient ischemic attack, myocardial
infarction, angina, coronary heart disease, cardiac death, coronary revascularization, and vas-
cular diseases), and effect estimates with accompanying 95% confidence intervals. The
extracted forms were reviewed (H.T.) for accuracy with the source paper.
Risk of bias
To assess the quality of abstracted information, including the clarity of reporting study meth-
ods, error, and bias, we used questions adapted from the 32-item questionnaire developed by
Downs and Black to rate patient intervention studies [16]. Following the approach of other sys-
tematic reviews [17–19], we removed items irrelevant to observational studies not studying an
intervention as the primary exposure. Due to a lack of validation, we did not calculate a com-
posite quality score but report scores in the appendix. Since the number of studies we included
was low, we did not report the results of the Eggers test.
Data synthesis and analysis
We performed qualitative and quantitative syntheses. We organized our findings according to
type of herpes zoster, outcome (cerebrovascular or coronary event), and time examined
between the onset of herpes related illness and our pre-defined disease outcomes. We consid-
ered meta-analysis when 2 or more studies could be pooled after evaluating the studies for clin-
ical and statistical heterogeneity. Clinical heterogeneity was examined by evaluating for
differences in study population, intervention or comparators. Statistical heterogeneity was esti-
mated using the I2 statistic to evaluate both the random and fixed effects models. I2 values of
30–60% represented a moderate level of heterogeneity [20].
We conducted both random and fixed effects meta-analysis. We conducted random effects
meta-analysis using the inverse variance method for pooled odds ratios (ORs). We used the
fixed effects model when the number of studies was low. We assumed similarity between the
Ors and other relative measures, such as relative risk, rate ratios, or hazard ratios because the
Herpes zoster and cardiovascular events
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cardiac events examined were relatively infrequent (< 1/10) events [21]. Where possible, we
pooled adjusted Ors from the primary studies; otherwise, we used the unadjusted Ors with no
correction for baseline differences or confounding. We assessed for publication bias using the
Eggers test. All meta-analyses were conducted in Stats Direct.
Since prior studies have reviewed the association between herpes zoster and cerebrovascu-
lar events, but not cardiac events, and estimated pooled ORs, we summarized the findings of
these studies forest plots to facilitate comparisons with our results.
Results
From the 1,617 unique articles initially identified in searches of electronic databases, 14 articles
were selected for full-text review after title and abstract review as shown in the PRISMA flow
sheet of included studies (Fig 1). Of these, twelve studies satisfied criteria for inclusion in this
review (Table 1).
Study characteristics
Table 1 presents an overview of the eight retrospective cohort studies [22–30] and three self-
case controlled case series [31–33] included in this review. We included self-controlled case
series since these studies have a design akin to that of an efficient cohort study that minimizes
confounding and produces measures of association, unlike a traditional case series [34]. The
studies sampled populations from six countries including enrollees of the national health
insurance systems in Taiwan [23, 25, 28, 29] and South Korea [24], Danish hospital and pre-
scription drug users [26], British primary care patients [22, 31], American Medicare enrollees
65 years and older [32], residents 50 years and older in Olmsted County (MN, US) [30], enroll-
ees of four private insurers in Germany [33] and residents of Västra Götaland County, Sweden
[27]. All included studies performed retrospective reviews of electronic medical record data-
bases; no study prospectively followed patients.
Fig 1. PRISMA flow chart describing the process for identifying included articles.
https://doi.org/10.1371/journal.pone.0181565.g001
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Table 1. Overview of included studies examining the association of herpes zoster and its subtypes with cardiovascular events.
Reference
(Year)
Country Study Design Population
Studied
Sample
Size
Age
Range
(Years)
Sample
Age
(Years)
Follow
Up
Period
(Years)
Herpes
Zoster Type
(s)
Examined
Assessment of
Exposure and
Outcomes
Outcomes
Examined
Breuer et al.
(2014)
United
Kingdom
Retrospective
matched
cohort
Patients of 464
primary care
clinics (2002 to
2010)
319,803  18 MN: 57.8 24 HZ, HZO READ, THIN
codes
Stroke, TIA,
MI
Kang et al.
(2009)
Taiwan Retrospective
matched
cohort
Random
sample of
National Health
Insurance
enrollees (1997
to 2001)
31,040  18 MN: 46.7 1 HZ, HZO ICD-9-CM
codes
Stroke
Kwon et al.
(2016)
South
Korea
Retrospective
cohort
Random
sample of
National Health
Insurance
enrollees
(2002–2013)
766,179  18 MN: 41.4 11 HZ ICD-10 codes Composite
of Stroke
and TIA
Langan et al.
(2014)
United
Kingdom
Self-controlled
case-series
Patients
receiving care
at 625 primary
care clinics
(1987 to 2012)
6,584  18 MD: 77 25 HZ, HZO CPRD, READ,
ICD-10 codes
Stroke
Lin et al.
(2010)
Taiwan Retrospective
matched
cohort
National Health
Insurance
Service
enrollees (2003
to 2005)
2,632  18 MN: 56.9 1 HZO ICD-9-CM
codes
Stroke
Minassian
et al. (2016)
USA Self-controlled
case-series
Medicare
enrollees 65
years and older
(2006 to 2011)
42,954
(Stroke),
24,237
(MI)
 65 MD: 81.1
(Stroke),
80.3 (MI)
6 HZ, HZO ICD-9-CM
codes, receipt of
antiviral therapy
(for HZ/HZO)
Ischemic
stroke, MI
Schink et al.
(2016)
Germany Self-controlled
case-series
Enrollees of
four insurance
providers
(2004–2011)
124,462  0 MN: 71.3 1 HZ, HZO ICD-10-GM
codes
Stroke
Sreenivasan
et al. (2013)
Denmark Retrospective
Cohort
All hospital and
prescription
users (1995 to
2008)
4,620,980  18 NR 13 HZ Prescription
records (HZ),
ICD-10 codes
(Stroke/TIA)
Composite
of Stroke
and TIA
Sundström
et al. (2015)
Sweden Retrospective
Cohort
All residents of
Västra
Götaland
County (2008–
2010)
1.5 million  0 NR 1 HZ ICD-10 Codes Stroke
Wang et al.
(2014)
Taiwan Retrospective
matched
cohort
Enrollees of
national
insurance
program (1999
to 2010)
289,790  0 NR 12 HZ ICD-9-CM
codes
ACS
Wu et al.
(2015)
Taiwan Retrospective
matched
cohort
Random
sample of
National Health
Insurance
enrollees (1998
to 2008)
97,415  20 MN: 46.4 10 HZ ICD-9-CM
codes
CAD
(Continued )
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As exposures, six of the included studies examined any form of herpes zoster (herpes zoster
type unspecified, which includes herpes zoster ophthalmicus) [24, 26–30], five examined her-
pes zoster type unspecified with sub-group analyses for herpes zoster ophthalmicus [22, 23,
31–33], and one study only examined patients with herpes zoster ophthalmicus [25].
Included studies examined cerebrovascular and cardiovascular events over time periods
ranging from 1 week to 24 years after onset of herpes zoster. The studies used a heterogeneous
definition of cerebrovascular and cardiac events. Eleven of the included studies examined asso-
ciations between herpes zoster type unspecified and the following: non-specified stroke [22,
23, 27, 30, 31, 33], ischemic stroke [32, 33], hemorrhagic stroke [33] [33], TIA [22], a compos-
ite of stroke and TIA [24, 26], myocardial infarction [22, 30, 32], acute coronary syndromes
(e.g., acute myocardial infarction and unstable angina) [28], and incident coronary artery dis-
ease, including angina and myocardial infarction [29]. Among studies examining patients with
herpes zoster ophthalmicus, five studies examined non-specified stroke [22, 23, 25, 31, 33],
two studies examined ischemic stroke [32], one examined hemorrhagic stroke [33], and one
examined myocardial infarction [32] as endpoints.
Quality of included studies. The details of the quality scores are presented in S2 File. The
included cohort studies presented limited data on potential confounders, particularly on
patient lifestyle practices that may lead to cerebrovascular or cardiovascular events [22–30].
While the self-controlled case series had limited measures of patient characteristics, their use
of patients as their own controls adjusted for time-invariant confounders [31–33]. Besides
items covered by the quality instrument, we observed that the included studies relied only on
administrative codes to determine outcomes and/or pharmacy data to determine exposure sta-
tus respectively, and were susceptible to misclassification of outcome and exposure. Only two
studies used additional criteria, including medical record documentation [30] and prescription
records [32], in combination with diagnostic codes, to validate exposure to herpes zoster. We
also observed that the cohort studies did not account for the increased probability of finding
statistically significant associations due to large sample sizes [22, 23, 25–32].
Meta-analysis of herpes zoster and cerebrovascular events
In examining the relationships between herpes zoster, type unspecified, and cerebrovascular
events, five studies found significantly positive associations with non-specific stroke [22, 23,
27, 30, 31, 33], two studies found associations with ischemic stroke [32, 33], one study with
Table 1. (Continued)
Reference
(Year)
Country Study Design Population
Studied
Sample
Size
Age
Range
(Years)
Sample
Age
(Years)
Follow
Up
Period
(Years)
Herpes
Zoster Type
(s)
Examined
Assessment of
Exposure and
Outcomes
Outcomes
Examined
Yawn et al.
(2016)
USA Retrospective
matched
cohort
Residents of
Olmsted
country (MN)
(1986 to 2010)
24,295  50 MN: 68.1 28 HZ ICD-9-CM
codes, medical
record review
Stroke, MI
Abbreviations by alphabetic order: ACS: acute coronary syndromes, CAD: coronary artery disease (includes acute and subacute MI, angina pectoris), CM:
Clinical Modification, CPRD: Clinical Practice Research Datalink (electronic database of patients receiving care at more than 625 UK primary care clinics),
GM: German Modification, HZ: herpes zoster (type unspecified), HZO: herpes zoster ophthalmicus, ICD: International Classification of Diseases, MD:
median, MI: myocardial infarction MN: mean, READ: clinical coding system used by United Kingdom General Practitioners, THIN: The Health Improvement
Network (medical, prescription and demographic database on 3 million primary care patients in the UK), TIA: Transient Ischemic Attack
https://doi.org/10.1371/journal.pone.0181565.t001
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hemorrhagic stroke [33], one study with TIA [22], and two studies with a composite endpoint
of stroke and TIA [24, 26].
The results of the meta-analyses of the association of herpes zoster, type unspecified, and
cerebrovascular events stratified by the length of follow-up are shown in Fig 2. Meta-analyses
found that patients with herpes zoster were at significantly increased odds of a cerebrovascular
event within 3 months of onset using the random effects and fixed effects models (pooled Ors
for fixed and random effects models 1.34, 95% CI: 1.22 to 1.46). There was no evidence for sta-
tistical heterogeneity (I2 = 0.0%) for the pooled results for cerebrovascular events. Similarly,
the odds of a cerebrovascular event were significantly increased up to 1 year after herpes zoster
onset (pooled Ors for fixed and random-effects models 1.22, 95% CI: 1.15 to 1.29), but with
severe statistical heterogeneity (I2 = 99.7%). The odds of experiencing a cerebrovascular event
over periods of time greater than 1 year after herpes zoster onset was significant in the fixed
effects model (pooled OR 1.40, 95% CI: 1.38 to 1.43), but not the random effects model (pooled
OR 1.20, 95% CI: 0.82 to 1.75), with severe statistical heterogeneity (I2 = 99.7%).
Fig 2. Meta-analyses of the association of herpes zoster, type unspecified, and cerebrovascular
events stratified by length of follow-up.
https://doi.org/10.1371/journal.pone.0181565.g002
Herpes zoster and cardiovascular events
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Meta-analysis of herpes zoster and cardiac events
Overall, three studies found significantly positive associations between exposure to herpes zos-
ter, type unspecified, with myocardial infarction within one week [32], three months [30], or
twenty-four years after zoster onset [22], with acute coronary syndromes within 12 years after
zoster onset [28], and with incident coronary artery disease within two and 10 years after zos-
ter onset (Table 2) [29].
Meta-analyses of the association of herpes zoster, type unspecified, and various cardiac
events stratified by length of follow-up is shown in Fig 3. Patients with herpes zoster were at
Table 2. Summary of measures of association between herpes zoster (type unspecified)* and cardiovascular events in reviewed studies.
Outcome Reference Follow Up
Period After
HZ
n Events /
n with HZ
Adjustment Variables Measure of
Association**
Adjusted Association
Size (95% CI)
Cerebrovascular Events
Stroke
(Non-Specified)
Langan et al. 3 months 149** AGE IR 1.42 (1.21 to 1.68)
Schink et al. 3 months 352** AGE IRR 1.29 (1.16 to 1.44)
Yawn et al. 3 months 33 / 4,478 AGE, ARTHM, VASC OR 1.53 (1.01 to 2.33)
Yawn et al. 6 months 46 / NR AGE, HTN, VASC OR 1.28 (0.91 to 1.80)
Kang et al. 1 year 133 /
7,760
AGE, SEX, HTN, DM, CHD, HYPLIP,
RENAL, AF, HF, VALV, CRTD, INC,
URBN, GEO
HR 1.31 (1.06 to 1.60)
Sundström
et al.
1 year 111 /
13,269
AGE, SEX IRR 1.34 (1.12 to 1.62)
Yawn et al. 1 year 71 / NR AGE, SEX, HTN, DYSLIP, CHD, VASC OR 1.04 (0.79 to 1.36)
Yawn et al. 3 years 176 /
4,151
AGE, SEX, HTN, DYSLIP, CHD, VASC,
DEP
OR 1.02 (0.86 to 1.22)
Breuer et al 24 years 2,727 /
106,601
AGE, SEX, BMI, SMK, HYPLIP, HTN,
DM, CHD, AF, PVD, CRTD, VALV
HR 1.02 (0.98 to 1.07)
Ischemic
Stroke
Minassian
et al.
1 week 499** AGE IR 2.37 (2.17 to 2.59)
Schink et al. 3 months 310** AGE IRR 1.27 (1.13 to 1.42)
Hemorrhagic
Stroke
Schink et al. 3 months 42** AGE IRR 1.53 (1.11 to 2.11)
TIA Breuer et al. 24 years 2,275 /
106,601
AGE, SEX, BMI, SMK, HYPLIP, HTN,
DM, CHD, AF, PVD, CRTD, VALV
HR 1.15 (1.09 to 1.21)
Stroke and TIA Sreenivasan
et al.
2 weeks 83 /
117,926
AGE, SEX, SN IRR 2.27 (1.83 to 2.82)
Sreenivasan
et al.
1 year 4,876 /
117,926
AGE, SEX, SN IRR 1.21 (1.14 to 1.29)
Sreenivasan
et al.
1 year 1.05 (1.02 to 1.09)
Kwon et al. 11 years 5,069 /
77,781
AGE, SEX, HTN, HYPLIP, CHD, DM, HF,
PVD, AF, RENAL, VALV
IRR 1.90 (1.85 to 1.95)
*Cases of herpes zoster ophthalmicus were included in all cases of the exposures,
** Comparison of patients with herpes zoster to those without (referent group)
Abbreviations (Alphabetically): AF: atrial fibrillation, ARTHM: arrhythmia, BMI: body mass index, CLIN: frequency of clinical visits, CNCR: cancer, CRTD:
carotid disease, CHD: coronary heart disease, COPD: chronic obstructive pulmonary disease, CVD: cerebral vascular disease, DEP: depression, DM:
diabetes mellitus, GEO: geographical region, HF: heart failure: HR: hazard ratio, HYPLIP: hyperlipidemia, HTN: hypertension, HZ: Herpes Zoster, INC:
income, IR: incidence ratio, IRR: incidence rate ratio, MEDS: medication use, NR: not reported, OCC: occupation, PVD: peripheral vascular disease,
RENAL: renal disease, SCCS: self-controlled case series, SN: season, SMK: smoking statin, URBN: urbanization level of patient’s area of residence,
VALV: valvular disease
https://doi.org/10.1371/journal.pone.0181565.t002
Herpes zoster and cardiovascular events
PLOS ONE | https://doi.org/10.1371/journal.pone.0181565 July 27, 2017 8 / 18
significantly increased odds of a cardiac event at 3 months after onset using the fixed effects
model (pooled OR 1.31, 95% CI: 1.02 to 1.70), but not the random effects model (pooled OR
1.34. 95% CI 0.98 to 1.82). We found a low level of statistical heterogeneity (I2 = 23.9%) for the
pooled results for myocardial infarction. The odds of a cardiac event up to 1 year after onset
were significantly higher using the fixed and random effects model (both pooled Ors 1.19, 95%
CI: 1.01 to 1.41). We found no evidence of statistical heterogeneity (I2 = 0.0%). Likewise, the
odds of a cardiac event over periods of greater than 1 year after zoster onset were significantly
higher using both the fixed and random effects models (both pooled Ors 1.12, 95% CI: 1.08 to
1.16). We found no evidence of statistical heterogeneity (I2 = 0.0%).
Meta-analysis of herpes zoster ophthalmicus and cerebrovascular
events
Exposure to herpes zoster ophthalmicus was statistically significantly associated with develop-
ment of non-specific stroke over time periods of up to one year in four studies [23, 25, 31, 33],
with the development of ischemic stroke over periods up to three months in two studies
Fig 3. Meta-analyses of the association of herpes zoster, type unspecified, and cardiac events
stratified by length of follow-up.
https://doi.org/10.1371/journal.pone.0181565.g003
Herpes zoster and cardiovascular events
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[32, 33], but not with hemorrhagic stroke [33] (Table 3). Meta-analyses of the association of
herpes zoster ophthalmicus and cerebrovascular events stratified by length of follow up are
shown in Fig 4. Compared with unexposed individuals, patients with herpes zoster ophthalmi-
cus were at significantly increased odds of cerebrovascular events within 3 months of illness
onset in meta-analyses using fixed-effects (pooled OR 1.39, 95% CI: 1.25 to 1.54) and random
effects (pooled OR 1.85, 95% confidence interval 1.09 to 3.12) models. We found a high level
of statistical heterogeneity (I2 = 88.9%) for the pooled results for cerebrovascular events. Simi-
larly, patients exposed to herpes zoster ophthalmicus had an increased odds of cerebrovascular
events within 1 year of onset in meta-analyses using both the fixed and random effects models
(both pooled ORs 4.42, 95% confidence interval 2.75 to 7.11), without any evidence of statisti-
cal heterogeneity (I2 = 0%).
Table 3. Summary of measures of association between herpes zoster (type unspecified)* and cardiac events in reviewed studies.
Outcome Reference Follow Up
Period After
HZ
n Events /
n with HZ
Adjustment Variables Measure of
Association**
Adjusted
Association Size
(95% CI)
Cardiac Events
Myocardial
Infarction
Minassian
et al
1 week 213** AGE IR 1.68 (1.47 to 1.92)
Yawn et al. 3 months 24 / 4,405 AGE, CHD OR 1.68 (1.03 to 2.75)
Yawn et al. 6 months 35 / NR AGE, CHD, DM OR 1.44 (0.97 to 2.15)
Yawn et al. 1 year 61 / NR AGE, SEX, CHD, DM, DEP OR 1.33 (0.99 to 1.80)
Yawn et al. 3 year 154 /
4,102
AGE, SEX, HTN, CHD, DM OR 1.17 (0.97 to 1.41)
Breuer et al. 24 years 2,762 /
106,601
AGE, SEX, BMI, SMK, DYSLIP, HTN, DM,
CHD, AF, PVD, CRTD, VALV
HR 1.10 (1.05 to 1.16)
Acute Coronary
Syndromes
Wang et al. 3 months 58 /
57,958
AGE, SEX, URBN, INC, OCPTN, CLIN,
HTN, DM, HYPLIP, CVD, COPD, RENAL,
CNCR, MEDS
HR 1.20 (0.89 to 1.62)
Wang et al. 1 year 193 /
57,958
AGE, SEX, URBN, INC, OCPTN, CLIN,
HTN, DM, HYPLIP, CVD, COPD, RENAL,
CNCR, MEDS
HR 1.14 (0.94 to 1.39)
Wang et al. 12 years 860 /
57,958
AGE, SEX, URBN, INC, OCPTN, CLIN,
HTN, DM, HYPLIP, CVD, COPD, RENAL,
CNCR, MEDS
HR 1.15 (1.07 to 1.24)
Coronary Artery
Disease
Wu et al. 2 years 388 /
19,483
AGE, SEX, DM, HTN, HYPLIP HR 1.14 (1.02 to 1.28)
Wu et al. 10 years 1,057 /
19,483
AGE, SEX, DM, HTN, HYPLIP HR 1.11 (1.04 to 1.19)
*Cases of herpes zoster ophthalmicus were included in all cases of the exposures,
** Comparison of patients with herpes zoster to those without (referent group)
Abbreviations (Alphabetically): AF: atrial fibrillation, ARTHM: arrhythmia, BMI: body mass index, CLIN: frequency of clinical visits, CNCR: cancer, CRTD:
carotid disease, CHD: coronary heart disease, COPD: chronic obstructive pulmonary disease, CVD: cerebral vascular disease, DEP: depression, DM:
diabetes mellitus, GEO: geographical region, HF: heart failure: HR: hazard ratio, HYPLIP: hyperlipidemia, HTN: hypertension, HZ: Herpes Zoster, INC:
income, IR: incidence ratio, IRR: incidence rate ratio, MEDS: medication use, NR: not reported, OCC: occupation, PVD: peripheral vascular disease,
RENAL: renal disease, SCCS: self-controlled case series, SN: season, SMK: smoking statin, URBN: urbanization level of patient’s area of residence,
VALV: valvular disease
https://doi.org/10.1371/journal.pone.0181565.t003
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Herpes zoster ophthalmicus and cardiac events
The one study to examine the association between herpes zoster ophthalmicus and acute car-
diac events showed that the relative frequency of myocardial infarction was significantly higher
in the first week after disease onset (Table 4) [32].
Overview of previous systematic reviews
The Forest plots from previous meta-analysis examining the association between herpes zoster,
type unspecified and herpes zoster ophthalmicus with stroke are shown in Fig 5. All meta-anal-
yses show a consistently positive relationship between herpes zoster and herpes zoster ophthal-
micus with stroke.
Discussion
Our systematic review and meta-analyses of twelve published epidemiological studies identi-
fied associations with exposure to herpes zoster with increased odds of 20 to 40% and 10 to
30% of experiencing a cerebrovascular and cardiovascular event, respectively, over periods of 3
months to over a year after onset. Similarly, compared with healthy controls, those exposed to
herpes zoster ophthalmicus may have twice to four times the odds of experiencing a cerebro-
vascular event, a relatively larger magnitude of effect, over periods of up to a year. To the best
of our knowledge, this is the first meta-analysis suggesting an association between herpes zos-
ter and cardiac events. These findings must be interpreted in the context of relatively small
magnitude of association, however, and the limited quality of included studies.
Our results also confirm the positive relationship between herpes zoster and herpes zoster
ophthalmicus with stroke found in prior meta-analyses [9–12]. Similar to our findings, these
four meta-analyses also found that the magnitude of association between herpes zoster and
Fig 4. Meta-analyses of the association of herpes zoster ophthalmicus and cerebrovascular events
stratified by length of follow-up.
https://doi.org/10.1371/journal.pone.0181565.g004
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stroke also declined over longer periods of follow-up. The one meta-analysis that examined
herpes zoster ophthalmicus did not show a substantial change in the pooled odds ratio of
experiencing a stroke at 3 months versus 1 year after herpes onset [11]. In contrast, our study
found a greater magnitude of association between herpes zoster ophthalmicus and cerebrovas-
cular events at one year compared to 3 months after herpes onset. This discrepancy may result
from limiting our analysis to observation periods soon after the onset of herpes zoster ophthal-
micus. In contrast, the prior meta-analysis incorporated measures of association from observa-
tion periods starting months after the diagnosis of herpes zoster ophthalmicus. Our analyses of
stroke with herpes zoster and herpes ophthalmicus also incorporated findings from one or
more contemporary publications that were not included in prior meta-analyses [33].
While recognizing that our results do not definitely prove herpes zoster to be a cause of car-
diovascular events, several plausible mechanisms exist to account for our findings. The devel-
opment of herpes zoster may lead to migration of VZV from the neurons to the cerebral and
coronary vasculature. This may lead to a local inflammatory response, causing vessel occlusion
and ultimately ischemia [35]. A case series of seven adults with symptoms of herpes zoster and
stroke or TIA found that these patients had cerebrospinal fluid samples that were positive for
VZV DNA and anti-VZV antibodies [36][35]. Arterial biopsies from patients with shingles
and stroke showed the presence of intranuclear Cowdry A inclusions consistent with VZV
Table 4. Summary of measures of association between herpes zoster ophthalmicus and cardiovascular events in reviewed studies.
Outcome Reference Follow Up
Period After
HZO
n Events
/
n with
HZ
Adjustment Variables Measure of
Association*
Adjusted Association
Size (95% CI)
Cerebrovascular Events
Stroke
(Non-Specified)
Schink et al. 3 months 31* AGE IRR 1.59 (1.10 to 2.32)
Langan
et al.
4 months 22* AGE IR 3.38 (2.18 to 5.24)
Kang et al. 1 year 7 / 120 AGE, SEX, HTN, DM, CHD, HYPLYP,
RENAL, AF, HF, VALV, CRTD, INC, URBN,
GEO
HR 4.28 (2.01 to 9.03)
Lin et al. 1 year 53 / 658 AGE, SEX, HTN, HYPLIP, DM, CHD, RHD,
MEDS
HR 4.52 (2.45 to 8.33)
Breuer et al. 24 years 68 /
1,710
AGE, SEX, BMI, SMK, DYSLIP, HTN, DM,
CHD, AF, PVD, CRTD, VALV
HR 1.03 (0.77 to 1.39)
Ischemic Stroke Minassian
et al.
1 week 93* AGE IR 2.73 (2.22 to 3.35)
Minassian
et al.
3 months 326* AGE IR 1.29 (1.15 to 1.44)
Schink et al. 3 months 27* AGE IRR 1.57 (1.05 to 2.35)
Hemorrhagic
Stroke
Schink et al. 3 months 4* AGE IRR 1.82 (0.62 to 5.37)
Coronary Events
Myocardial
Infarction
Minassian
et al.
1 week 43
(SCCS)
AGE IR 2.06 (1.52 to 2.79)
* Comparison of patients with herpes zoster to those without (referent group)
Abbreviations (Alphabetically): AF: atrial fibrillation, BMI: body mass index, CLIN: frequency of clinical visits, CNCR: cancer, CRTD: carotid disease,
CHD: coronary heart disease, COPD: chronic obstructive pulmonary disease, CVD: cerebral vascular disease, DEP: depression, DM: diabetes mellitus,
GEO: geographical region, HF: heart failure: HR: hazard ratio, HYPLIP: hyperlipidemia, HTN: hypertension, HZ: Herpes Zoster, INC: income, IR: incidence
ratio, IRR: incidence rate ratio, MEDS: medication use, NR: not reported, OCC: occupation, PVD: peripheral vascular disease, RENAL: renal disease, SSN:
season, SMK: smoking statin, URBN: urbanization level of patient’s area of residence, VALV: valvular disease
https://doi.org/10.1371/journal.pone.0181565.t004
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[37]. Patients with herpes zoster ophthalmicus could be susceptible to a cerebrovascular event
due to the proximity of the trigeminal ganglion to the cerebral arteries; our meta-analytic
results showed a more than two-fold increased odds of cerebrovascular events among patients
with a history of herpes zoster ophthalmicus. Herpes zoster could also produce systemic
inflammation, autoimmune responses, or hemodynamic changes leading to cardiovascular
events [22, 32, 38].
Moreover, the association between herpes zoster and cardiovascular events could result
from both diseases sharing similar precipitating factors. For instance, illness and psychological
stress have been separately identified as independent triggers of herpes zoster and acute myo-
cardial infarction [39, 40]. If such common factors were the cause for the observed associa-
tions, we would have expected that results from the reviewed self-controlled case series would
have been closer to the null hypothesis [31–33]. Future studies in this area would benefit from
the assessment of, and accounting for, common causes and/or triggers of herpes zoster and
acute cardiac events.
Since most of the evidence included in this review came from retrospective studies of claims
data, additional study is warranted to confirm and better characterize the magnitude and tim-
ing of potential cardiovascular complications following herpes zoster. While many of these
studies had the benefit of using large cohorts that were representative of general populations,
past reviews of medical records suggest that some misclassification of patients with diagnostic
codes for stroke, myocardial infarction, and herpes zoster can occur [41–43]. Subsequent stud-
ies may be improved by applying more stringent criteria for the diagnosis of herpes zoster (i.e.,
viral PCR or direct fluorescence antigen testing), stroke (i.e., computed tomography or mag-
netic resonance imaging), and acute cardiac events (elevated cardiac biomarkers or serial elec-
trocardiographic changes) [44–46]. Moreover, with the exception of herpes zoster
ophthalmicus, claims data may lack information on the dermatomal distribution of the pre-
senting zoster. Conceivably, the risk of cardiovascular events may depend on whether the
Fig 5. Results of prior meta-analyses examining the association between herpes zoster and herpes
zoster ophthalmicus with stroke.
https://doi.org/10.1371/journal.pone.0181565.g005
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herpes zoster outbreak occurs in dermatomes that share innervation with the coronary and
cerebral arteries.
Additional studies of cardiovascular outcomes among patients receiving vaccination
against, as well as antiviral therapy for, herpes zoster could provide a better understanding of
herpes zoster as a possible risk factor for cardiovascular diseases. For instance, data that sug-
gests that those receiving vaccinations against influenza have decreased rates of acute coronary
syndromes have provided evidence for the pathogen as being a trigger for cardiac events [47,
48]. Future cohort studies or (preferably) randomized trials examining the occurrence of car-
diovascular events among those receiving the shingles vaccine could lead to better clarification
of the possible relationship between herpes zoster and the outcomes suggested by our results.
Although the Food and Drug administration has approved use of the shingles vaccine in
person 50 years and older, the Centers for Disease Control (CDC) only recommends vaccina-
tion against herpes zoster for all adults 60 years and older [49]. The CDC does not have a rec-
ommendation for the use of vaccine for those in the 50 to 59 year age group. The lack of
recommendations for this age group is based on the low incidence of herpes zoster in the age
group, limited duration of the efficacy of the vaccine, and lack of evidence for cost-effective-
ness [49, 50]. However, age-stratified sub-group analyses from several of the studies included
in this review suggest that patients younger than 60 years may have a heightened risk of cardio-
vascular events following herpes zoster [22, 24, 26–28]. Since published trials on herpes zoster
vaccine lack data on the frequency of cardiac events in populations both less than and greater
than 60 years old [51, 52], further research is required for the potential for vaccination against
herpes zoster to reduce cardiovascular events, possibly in age-groups that do not traditionally
receive the vaccine.
While our results are insufficient to suggest changes in clinical practice, consideration is
warranted on research for potential management strategies for patients with herpes zoster if
there is the potential that these individuals may have a greater likelihood of future cardiovascu-
lar events. As historical results suggest that the public generally possesses limited knowledge
about the acute symptoms of stroke and myocardial infarction, future work could examine
educating patients with herpes zoster about the symptoms of acute coronary disease [53, 54].
Moreover, future research may consider the effects of antiviral therapy on the subsequent
risk of cardiovascular events among patients with herpes zoster. In general, recommendations
suggest treatment of herpes zoster with a guanosine analogue, such as acyclovir, within 72
hours of the development of acute symptoms or in the presence of other criteria, such as being
older or immunosuppressed [44]. Since such guidelines were developed with the intention of
managing pain and neurologic complications from herpes zoster, treatment for the prevention
of cardiovascular events may be different. Limited observational analyses suggest that patients
receiving antiviral therapy after the onset of herpes zoster may have decreased risks of
experiencing subsequent cardiovascular events[25, 28, 31] but investigations using data from
randomized, controlled studies would likely be required for more definitive evidence.
We acknowledge several limitations of this review which primarily reflect the quality of
reported data. We could not conduct time to event analysis in the absence of individual level
data. We may have missed some studies that were not published in English. Positive-results
bias may have prevented the publication of studies that did not find an association between
herpes zoster and selected cardiovascular events. Four studies included in this review sampled
enrollees in a Taiwanese health insurance program; while each of those studies sampled
slightly different populations, the results of these studies could potentially have a similar error
or biases that would not occur from studies that used more diverse data sources. All of the
included studies utilized a retrospective design that ascertained exposure and outcomes
through diagnosis codes—only two studies confirmed the diagnosis of herpes zoster with
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additional record review of microbiology data [30,32]. Moreover, these studies could not
account for patients who developed herpes zoster and/or a cardiovascular event and did not
seek medical treatment.
Conclusions
Our systematic review and meta-analysis suggests that the occurrence of cerebrovascular and
cardiac events increases following the development of herpes zoster, although the magnitude
of the effect is small and the quality of evidence is limited. Further studies are needed to char-
acterize this relationship and to determine whether more aggressive prevention of herpes zos-
ter through vaccination could reduce the burden of cerebrovascular and cardiovascular disease
associated with this infection. Future studies should also identify optimal approaches for the
treatment and surveillance of patients with herpes zoster to mitigate their possibly heightened
risk of cerebrovascular and cardiovascular events.
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